Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

US distribution agreement

29 Jul 2008 07:00

RNS Number : 0596A
LiDCO Group Plc
29 July 2008
 



Press Release 

29 July 2008

LiDCO Group Plc

("LiDCO" or the "Company")

US distribution agreement

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce it has signed an exclusive distribution agreement with US speciality distributor KOL Bio Medical Instruments (KOL) for the sale of the LIDCOrapid Monitor in certain territories in the US. 

It is estimated that the American market for minimally invasive hemodynamic monitoring market for high risk surgery is currently valued at US$238m. 

KOL is a 37 year old speciality distributor of medical technology with extensive experience of selling hemodynamic monitoring equipment. The company has a 15 strong specialist sales team and currently supplies to 21 states on the Eastern side of the USA. LiDCO also distributes to other parts of the USA via its own sales force of 5 people. This combined and significantly enlarged sales force gives LiDCO access to more than 40% of US market. LiDCO expects there will be additional distributor appointments for the states not currently covered by either sales force. 

Timothy McInerney CEO of KOL (www.kolbio.com) said: "We have been very impressed with the LiDCOrapid Monitor. We have seen an increased demand from the US healthcare market for an easy to use, minimally invasive, precise hemodynamic monitoring product for surgery. The release of the LiDCOrapid is very timely, since the continuing downward trend in the use of thermodilution catheters has left many US physicians without an effective way to monitor and manage the key variables associated with optimal hemodynamic performance. The minimally invasive LiDCOrapid provides the perfect dashboard for assessment and control of these critical parameters in medium to high risk patients. It appears to be the perfect solution at a perfect time."

Dr Terry O'Brien, CEO of LiDCO, commented: "I am delighted to be working with KOL. The company has an eminent reputation and for some time has been one of the leading medical distributors in the US. Together with KOL we have seen strong interest for the LIDCOrapid Monitor in the US, since we launched in April this year. I anticipate that this partnership will be very productive for both companies." 

- ENDS - 

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com 

Panmure Gordon and Co

Edward Farmer/ Katherine Roe

+44 (0)20 7459 3600

www.panmure.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0)20 7398 7728

simone.alves@abchurch-group.com 

www.abchurch-group.com 

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus and PulseCO monitors: these computer-based platforms are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

LiDCOrapid provides:

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care advantages:

Contributes to reduced morbidity and complications

Reduces length of stay

Reduces overall cost of care

* LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors

LiDCO Distribution Network:

The Company sells direct in the UK, direct and through partners in the USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRPMRTMMMTBMP
Date   Source Headline
26th Apr 20107:00 amRNSPreliminary Results
3rd Mar 20104:25 pmRNSSale of Employee Benefit Trust shares
25th Feb 20107:00 amRNSPre-close trading update & notice of Results & AGM
2nd Feb 20107:00 amRNSLiDCO featured in case study from Intel
4th Nov 20097:00 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
29th Oct 20097:00 amRNSInterim Results
19th Oct 20097:00 amRNSAspect launches LiDCOrapid at ASA annual meeting
5th Oct 20097:00 amRNSNotice of Results
5th Oct 20097:00 amRNSWelcomes Covidien acquisition of Aspect Medical
1st Sep 20097:00 amRNSLIDCOrapid chosen for UK OPTIMISE study
19th Aug 20097:00 amRNSTrading Statement
29th Jul 20097:00 amRNSExclusive US-wide distribution agreement
16th Jul 20097:00 amRNSSoftware upgrade for the LiDCOrapid
7th Jul 20091:48 pmRNSIssue of Equity
24th Jun 20095:00 pmRNSTR-1: Notification of Major Interests in Shares
24th Jun 200912:08 pmRNSResult of AGM
28th May 20094:15 pmRNSGrant of Share Options
22nd May 20095:11 pmRNSTR-1: Notifications of Major Interests in Shares
22nd May 20097:00 amRNS2009 Annual Report and Accounts
21st May 20097:00 amRNSIssue of Equity
21st Apr 20097:00 amRNSFinal Results
16th Apr 20097:00 amRNSLiDCO Extends Collaboration With BD
6th Apr 20097:00 amRNSChange of Adviser
10th Mar 20097:00 amRNSDistribution expansion
3rd Mar 200912:47 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSNotice of Results and AGM
5th Feb 20094:13 pmRNSHolding(s) in Company
13th Jan 20097:00 amRNSDistribution expansion
30th Oct 20087:01 amRNSInterim Results
30th Oct 20087:00 amRNSLiDCO chosen for clinical trial
28th Oct 20087:00 amRNSDuke University submits US$250,000 order
14th Aug 20087:00 amRNSNew Loan Arrangement and Noti
29th Jul 20087:00 amRNSUS distribution agreement
4th Jul 200812:23 pmRNSHolding(s) in Company
25th Jun 200811:29 amRNSResult of AGM
19th Jun 20087:00 amRNSClinical Evidence
30th May 20087:00 amRNSAnnual Report and Accounts
28th Apr 20084:47 pmPRNDirector/PDMR Shareholding
25th Apr 200811:27 amRNSGrant of Share Options
24th Apr 20087:01 amRNSPreliminary Results
24th Apr 20087:01 amRNSFinance Director Appointment
21st Apr 20087:00 amRNSLaunch of LiDCOrapid Monitor
4th Mar 20087:00 amPRNPreview at World Congress
28th Feb 20087:00 amPRNTrading Update
26th Feb 20087:00 amPRNLiDCOview Pro Launch
25th Feb 20087:00 amPRNNotice of Results
30th Jan 20087:00 amPRNCanadian Distribution Agreement
31st Dec 20079:19 amRNSChange of Adviser
13th Dec 200711:44 amPRNGrant of Options
12th Dec 20077:00 amPRNResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.